Literature DB >> 2861710

Doxazosin increases low density lipoprotein receptor activity.

T P Leren.   

Abstract

The effect of the alpha 1 adrenoreceptor antagonist doxazosin on low density lipoprotein (LDL) receptor activity, has been studied in cultured skin fibroblasts. Doxazosin at a concentration of 10(-5) M significantly increased the LDL receptor activity. The possible clinical implications of this observation are discussed.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2861710     DOI： 10.1111/j.1600-0773.1985.tb01288.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN： 0001-6683


  8 in total

Review 1.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

Review 2.  Serum lipoproteins during treatment with antihypertensive drugs.

Authors:  P Weidmann; C Ferrier; H Saxenhofer; D E Uehlinger; B N Trost
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Effect of ketanserin tartrate on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.

Authors:  M Suzukawa; H Nakamura
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Glucagon, cyclic AMP and adrenaline stimulate the degradation of low-density lipoprotein by cultured rat hepatocytes.

Authors:  N F Brown; A M Salter; R Fears; D N Brindley
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

5.  Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.

Authors:  T L Foxall; G T Shwaery; A F Stucchi; R J Nicolosi; S S Wong
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

6.  Effects of ketanserin tartrate on 3-hydroxy, 3-methylglutaryl coenzyme A reductase activity in cultured human skin fibroblasts.

Authors:  M Suzukawa; H Nakamura
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 7.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 8.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.